Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective
Authors:
- Ivana StojanovicISIvana Stojanovic
- John E. SchneiderJSJohn E. Schneider
- Long WeiLWLong Wei
- Zhan HongZHZhan Hong
- Clara KeaneCKClara Keane
- Philipp SchuetzPSPhilipp Schuetz
- 1 January 2017
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (4) , 561-570
Abstract
Background: Cost-impact models have indicated that in the USA, the use of antibiotic stewardship protocols based on procalcitonin (PCT) levels for patients with suspected acute respiratory tract infection results in cost savings. Our objective was to assess the cost impact of adopting PCT testing among patients with acute respiratory infections (ARI) from the perspective of a typical hospital system in urban China.Methods: To conduct an economic evaluation of PCT testing versus usual care we built a cost-impact model based on a previously published patient-level meta-analysis data of randomized trials including Chinese sites. The data were adapted to the China setting by applying the results to mean lengths of stay, costs, and practice patterns typically found in China. We estimated the annual ARI visit rate for the typical hospital system (assumed to be 1650 beds) and ARI diagnosis.Results: In the inpatient setting, the costs of PCT-guided care compared to usual care for a cohort of 16,405 confirmed ARI patients was almost 1.1 million Chinese yuan (CNY), compared to almost 1.8 million CNY for usual care, resulting in net savings of 721,563 CNY to a typical urban Chinese hospital system for 2015. In the ICU and outpatient settings, savings were 250,699 CNY and 2.4 million CNY, respectively. The overall annual net savings of PCT-guided care was nearly 3.4 million CNY.Conclusions: Substantial savings are associated with PCT protocols of ARI across common China hospital treatment settings mainly by direct reduction in unnecessary antibiotic utilization.Keywords
This publication has 63 references indexed in Scilit:
- Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumoniaCurrent Opinion in Infectious Diseases, 2013
- Influence of procalcitonin on decision to start antibiotic treatment in patients with a lower respiratory tract infection: insight from the observational multicentric ProREAL surveillanceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Do sepsis biomarkers in the emergency room allow transition from bundled sepsis care to personalized patient care?Current Opinion in Critical Care, 2012
- Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-AnalysisClinical Infectious Diseases, 2012
- Procalcitonin Algorithms for Antibiotic Therapy DecisionsArchives of internal medicine (1960), 2011
- Biomarkers as a guide for antimicrobial therapyInternational Journal of Antimicrobial Agents, 2010
- The Clinical Utility of Precision Medicine: Properly Assessing the Value of Emerging Diagnostic TestsClinical Pharmacology & Therapeutics, 2010
- Factors Associated With Variation in Estimates of the Cost of Resistant InfectionsMedical Care, 2010
- Effect of Procalcitonin-Guided Treatment in Patients with Infections: a Systematic Review and Meta-AnalysisInfection, 2009
- Retrospective analysis of nosocomial infections in the intensive care unit of a tertiary hospital in China during 2003 and 2007BMC Infectious Diseases, 2009